SK Plasma has expanded its portfolio of treatments for rare and severe blood disorders with the launch of 'Revolpax,' a medication for low platelet count. The company aims to strengthen its blood disorder treatment business based on its accumulated capabilities in blood products.
On August 3, SK Plasma announced that it will begin supplying 'Revolpax 25mg and 50mg' domestically, following its approval from the Ministry of Food and Drug Safety in May. The health insurance reimbursement limits, effective from August 1, are set at 28,398 won and 55,188 won, respectively.
Revolpax contains eltrombopag olamine, a treatment for low platelet count that works by stimulating platelet production in the bone marrow. It is used for chronic immune thrombocytopenia and severe aplastic anemia.
Immune thrombocytopenia is a blood disorder where the immune system attacks platelets, leading to a decrease in their numbers and making patients prone to bruising and bleeding. Revolpax is used to increase platelet counts in patients with chronic immune thrombocytopenia who do not respond adequately to standard treatments such as corticosteroids or immunoglobulins.
Severe aplastic anemia is a rare blood disorder characterized by a decrease in the bone marrow's ability to produce blood cells, including red blood cells, white blood cells, and platelets. Revolpax can be taken alongside immunosuppressive therapy or used in patients who do not respond sufficiently to such therapy to promote platelet production.
Plasma-derived products are classified as essential medicines by the World Health Organization (WHO) and are used in the treatment of severe diseases, making them difficult to replace. Countries without production capabilities are highly dependent on imports, which can expose them to supply chain disruptions during times of instability.
SK Plasma is a specialized company in plasma-derived products, reliably producing and supplying essential medicines such as albumin and immunoglobulin. Following the launch of its hemophilia treatment, the company plans to continue expanding its portfolio of treatments for rare and severe blood disorders and ensure a steady supply of necessary medications for patients.
Kim Seung-joo, CEO of SK Plasma, stated, "For patients with rare and intractable diseases, every new treatment option is crucial, even if the number of patients is small. We will leverage our expertise in blood disorders to broaden patient choices and expand into areas of rare and intractable diseases where treatments have yet to be developed."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.